Moleculin, based in Houston, TX, is a biopharmaceutical company focused on developing innovative therapies for highly resistant cancers and viruses. Their priority development pipeline includes next-generation anthracyclines, immune transcription modulators, STAT3 inhibitors, and metabolism glycosylation inhibitors.
With a growing portfolio of product candidates, Moleculin is dedicated to advancing better treatments for patients, aiming to provide hope for more tomorrows through their proprietary technologies and data-driven approach to combatting challenging diseases.
Generated from the website